Display Settings:

Format

Send to:

Choose Destination

See 1 citation found using an alternative search:

Lancet Infect Dis. 2012 Mar;12(3):240-8. doi: 10.1016/S1473-3099(11)70318-8. Epub 2011 Dec 18.

Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.

Author information

  • 1WHO Collaborating Centre for Reference and Research on Influenza, North Melbourne, VIC, Australia. aeron.hurt@infl uenzacentre.org

Abstract

Influenza A H1N1 2009 virus caused the first pandemic in an era when neuraminidase inhibitor antiviral drugs were available in many countries. The experiences of detecting and responding to resistance during the pandemic provided important lessons for public health, laboratory testing, and clinical management. We propose recommendations for antiviral susceptibility testing, reporting results, and management of patients infected with 2009 pandemic influenza A H1N1. Sustained global monitoring for antiviral resistance among circulating influenza viruses is crucial to inform public health and clinical recommendations for antiviral use, especially since community spread of oseltamivir-resistant A H1N1 2009 virus remains a concern. Further studies are needed to better understand influenza management in specific patient groups, such as severely immunocompromised hosts, including optimisation of antiviral treatment, rapid sample testing, and timely reporting of susceptibility results.

Copyright © 2012 Elsevier Ltd. All rights reserved.

PMID:
22186145
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk